---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-080641"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:42:34.410393+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Zymeworks appoints Dr. Neil Gallagher to board; 6th new director in 12 months

## Summary
- Dr. Gallagher joins board effective April 2, 2024 as Class I director, term to 2025 AGM.
- He will receive initial option grant for 74,000 common shares on appointment.
- Gallagher appointed to R&D committee; full committee composition updated (see filing).
- Gallagher is President & Head of R&D at Syndax Pharmaceuticals; ex-AbbVie, Amgen, Novartis.
- CEO says appointment supports advancement of '5 by 5' clinical programs and pipeline expansion.

## SEC filing metadata
- accession: 0001193125-24-080641
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/0001193125-24-080641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/d803711d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-080641
- JSON: https://secwatch.observer/filing/0001193125-24-080641.json
- Plain text: https://secwatch.observer/filing/0001193125-24-080641.txt

## Key facts
- Executive change
  Dr. Neil Gallagher was appointed as director at Zymeworks Inc..
  - Action: appointed
  - Role: director
  source text: On March 27, 2024, the board of directors (the “Board”) of Zymeworks Inc. (the “Company”), upon recommendation from the nominating and corporate governance committee of the Board, appointed Dr. Neil Gallagher as a director of the Company, effective as of April 2, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/0001193125-24-080641-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.